Unknown PHASE3 INTERVENTIONAL 2-arm NCT04694612

Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal

Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal: a Multi-center, Randomized, Open-labelled, Phase III Clinical Trial

Sponsor: Nepal Health Research Council

Conditions Covid19

Interventions Favipiravir Placebo Remdesivir

Updated 4 times since 2021 Last updated: Jan 3, 2021 Started: Jan 1, 2021 Primary completion: Mar 31, 2021 Completion: May 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04694612, this PHASE3 trial focuses on Covid19 and remains ongoing. Sponsored by Nepal Health Research Council, it has been updated 4 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Feb 2023 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Feb 2021 — Feb 2023 [monthly]

Recruiting PHASE3

First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nepal Health Research Council

Data source: Nepal Health Research Council

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kathmandu, Nepal
• Pokhara, Nepal